BioNTech (BNTX) to Release Quarterly Earnings on Monday

BioNTech (NASDAQ:BNTX - Get Free Report) will release its earnings data before the market opens on Monday, November 4th. Analysts expect BioNTech to post earnings of ($1.06) per share for the quarter. BioNTech has set its FY 2024 guidance at EPS.Individual that are interested in registering for the company's earnings conference call can do so using this link.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings data on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.02) by ($1.34). The firm had revenue of $128.70 million during the quarter, compared to analysts' expectations of $134.98 million. BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. BioNTech's revenue was down 23.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.86) EPS. On average, analysts expect BioNTech to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

BioNTech Trading Up 2.5 %

Shares of BioNTech stock traded up $2.78 during trading on Monday, reaching $113.26. 666,760 shares of the stock were exchanged, compared to its average volume of 782,553. BioNTech has a 1 year low of $76.53 and a 1 year high of $131.49. The firm has a market cap of $26.92 billion, a price-to-earnings ratio of 220.96 and a beta of 0.24. The company has a quick ratio of 7.40, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. The stock's fifty day moving average is $107.26 and its 200 day moving average is $94.98.

Analyst Ratings Changes

A number of brokerages have recently weighed in on BNTX. HC Wainwright lifted their price objective on BioNTech from $113.00 to $150.00 and gave the stock a "buy" rating in a research report on Monday, October 7th. Jefferies Financial Group raised shares of BioNTech from a "hold" rating to a "buy" rating and boosted their price objective for the company from $96.00 to $150.00 in a research report on Tuesday, September 17th. TD Cowen raised their target price on shares of BioNTech from $85.00 to $132.00 and gave the stock a "hold" rating in a research report on Monday, October 21st. Morgan Stanley raised shares of BioNTech from an "equal weight" rating to an "overweight" rating and lifted their target price for the company from $93.00 to $145.00 in a research note on Tuesday, September 24th. Finally, Deutsche Bank Aktiengesellschaft increased their price target on shares of BioNTech from $95.00 to $150.00 and gave the stock a "buy" rating in a research note on Thursday, September 19th. Five research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $135.54.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.